2. Immunology/Inflammation Apoptosis
  3. PD-1/PD-L1 Interleukin Related TNF Receptor
  4. Cetrelimab

Cetrelimab  (Synonyms: JNJ 63723283; JNJ 3283)

目录号: HY-P99499 纯度: 100.00%
COA

摩尔计算器

Cetrelimab (JNJ 63723283; JNJ 3283) 是一种靶向 PD-1 的人源 IgG4κ 单克隆抗体。Cetrelimab 结合 PD-1 的 Kd 为 1.72 nM (HEK293 细胞)。由此，Cetrelimab 阻断 PD-1 与 PD-L1 和 PD-L2 的相互作用 (IC50 分别为 111.7 ng/mL 和 138.6 ng/mL)。Cetrelimab 还刺激外周 T 细胞，增加细胞因子 (IFN-γ, IL-2, TNF-α) 水平，并抑制体内肿瘤生长。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Cetrelimab Chemical Structure

Cetrelimab Chemical Structure

CAS No. : 2050478-92-5

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥3000
In-stock
5 mg ￥7800
In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Customer Review

Cetrelimab 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo[1].

IC50 & Target

PD-1/PD-L1, PD-1/PD-L2, IFN-γ, IL-2, and TNF-α[1]
体外研究
(In Vitro)

Cetrelimab (0.01-30 nM; 5 d) 在活化 CD4+ 和 CD8+ T 细胞上与内源性 PD-1 结合，EC50 分别为 0.16-0.22 µg/mL 和 0.17-0.22 µg/mL[1]。
Cetrelimab (0.01-30 μg/mL; 24 h) 在表达 PD-L1 的 CHO-K1 的 Jurkat-PD-1 NFAT 报告细胞中逆转 PD-1 导致的 TCR 信号抑制[1]。
Cetrelimab (0.001-100 nM; 6 d) 增加 IFN-γ，IL-2，和 TNF-α，EC50 分别为 0.08 ng/mL，0.07 ng/mL，和 0.02 ng/mL[1]。
Cetrelimab 与猕猴来源的 PD-1 结合，Kd 值为 0.9 nM[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cetrelimab 相关抗体:
体内研究
(In Vivo)

Cetrelimab (10 mg/kg; 腹腔注射; 单剂量) 对带有 MC38 肿瘤的 PD-1 敲入 (hPD-1KI) 小鼠具有抗肿瘤作用，并能减小肿瘤体积[1]。
Cetrelimab (10 mg/kg; 腹腔注射; 每 5 天 1 次, 共 30 天) 在患者源性异种移植 (PDX) 小鼠肺癌模型中，外周血 CD8+ T 细胞显著增加[1]。
Cetrelimab (10-100 mg/kg; 静脉注射; 每周 1 次, 共 5 周) 在猕猴中具有良好的耐受性[1]。
Cetrelimab (0.1-10 mg/kg; 静脉注射; 单剂量, 监测 57 天) 在猕猴中显示出非线性的药代动力学 (PK) 特征，可能归因于靶介导药物沉积 (TMDD)[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: hPD-1KI model with mouse PD-1 ECD replaced by the human PD-1 ECD[1]
Dosage: 10 mg/kg
Administration: Intraperitoneal injection; single dose at day 7 after tumor implantation
Result: hPD-1KI mice develop normally and have no immune abnormalities.
Significantly lowered tumor volume at Day 21.
Animal Model: Patient-derived xenograft (PDX) LG1306 lung model in mice[1]
Dosage: 10 mg/kg
Administration: Intraperitoneal injection; every 5 days for 6 cycles
Result: Significantly reduced patient-derived tumor volume by 32%.
Animal Model: Good Laboratory Practice (GLP) toxicity study in cynomolgus[1]
Dosage: 0, 10, 30, or 100 mg/kg
Administration: Intravenous injection; once weekly for 5 weeks
Result: Showed well tolerance in cynomolgus.
Clinical Trial
CAS 号
性状

液体

颜色

Colorless to light yellow

运输条件

Shipping with dry ice.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料

纯度: 100.00%

COA (150 KB)

抗体抑制剂使用指南 (1152 KB)
参考文献

Cetrelimab 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cetrelimab2050478-92-5JNJ 63723283 JNJ 3283JNJ63723283JNJ-63723283JNJ3283JNJ 3283JNJ-3283PD-1/PD-L1Interleukin RelatedTNF ReceptorPD-1/Programmed death-ligand 1ILTumor Necrosis Factor ReceptorTNFRInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Cetrelimab
目录号：
HY-P99499
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z